Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
0.7000
-0.0540 (-7.16%)
At close: Apr 1, 2025, 4:00 PM
0.7443
+0.0443 (6.33%)
After-hours: Apr 1, 2025, 4:48 PM EDT
Salarius Pharmaceuticals Employees
Salarius Pharmaceuticals had 2 employees as of December 31, 2023. The number of employees decreased by 10 or -83.33% compared to the previous year.
Employees
2
Change (1Y)
-10
Growth (1Y)
-83.33%
Revenue / Employee
n/a
Profits / Employee
-$2,787,889
Market Cap
1.22M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SLRX News
- 8 days ago - Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers - GlobeNewsWire
- 2 months ago - Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge - Benzinga
- 10 months ago - Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 1 year ago - Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment - GlobeNewsWire
- 1 year ago - Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update - GlobeNewsWire